Log In
BCIQ
Print this Print this
 

SLITone

  Manage Alerts
Collapse Summary General Information
Company ALK-Abello A/S
DescriptionDroplet-based sublingual allergy vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsTreat birch pollen induced allergy; Treat IgE mediated allergy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$81.4M

$40.7M

$40.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/28/2011

$81.4M

$40.7M

$40.7M

Get a free BioCentury trial today